Population Modeling Approach in Bioequivalence Assessment

Pharmacometrics: The Science of Quantitative Pharmacology

Volumn , Issue , 2006, Pages 421-453

  Hu, Chuanpu ^a   Sale, Mark E ^b  

^a Global Health Outcomes and Market Access   (United States)

^b Next Level Solutions   (United States)

Author keywords

ANOVA; Area under the plasma concentration time curve (AUC); Bioequivalence (BE); Bootstrap; Confidence intervals; Nonlinear mixed effect modeling; Peak plasma concentration (Cmax) clearance; Pharmacodynamic bioequivalence; Population modeling; Sparsely sampled subjects; Structural model

Indexed keywords

EID: 84889347303     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470087978.ch16     Document Type: Chapter

References (21)

1. D. J. Schuirmann, A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15(6)):657-680 (1987).
2. Interim Guidance for Documentation of in Vivo Bioequivalence of Albuterol Inhalation Aerosols (Metered Dose Inhalers). Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, FDA, January 27, 1994.
3. N. Kaniwa, N. Aoyagi, H. Ogata, and M. Ishii, Application of the NONMEM method to evaluation of the bioavailability of drug products. J Pharm Sci 79(12)):1116-1120 (1990).
4. G. A. Maier, G. G. Lockwood, J. A. Oppermann, et al., Characterization of the highly variable bioavailability of tiludronate in normal volunteers using population pharmacokinetic methodologies. Eur J Drug Metab Pharmacokinet 24(3)):249-254 (1999).
5. H. S. Pentikis, J. D. Henderson, N. L. Tran, and T. M. Ludden, Bioequivalence: individual and population compartmental modeling compared to the noncompartmental approach. Pharm Res 13(7)):1116-1121 (1996).
6. D. M. Reith, W. D. Hooper, J. Parke, and B. Charles, Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults. J Pharmacokinet Biopharm 28(1)):79-92 (2001).
7. S. Senn, Statistical Issues in Drug Development. Wiley, Hoboken, NJ, 1997.
8. J. J. Faraway, On the cost of data analysis. J Comput Graphical Stat 1:213-229 (1992).
9. C. C. Peck and J. Wechsler, Report of a workshop on confirmatory evidence to support a single clinical trial as a basis for new drug approval. Drug Inf J 36:517-534 (2002).
10. B. Efron and R. J. Tibshirani, An Introduction to the Bootstrap. Chapman & Hall, New York, 1993.
11. F. Harrell, Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. Springer-Verlag, New York, 2001.
12. E. I. Ette, Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37:486-495 (1997).
13. W. R. Gilks, S. Richardson, and D. J. Spiegelhalter, Markov Chain Monte Carlo in Practice. Chapman & Hall, London, 1996.
14. E. Ette, P. J. Williams, Y. H. Kim, J. R. Lane, M. Liu, and E. V. Capparelli, Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol 43:610-623 (2003).
15. J. A. Johnson, Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci 86:1328-1333 (1997).
16. B. M. Sadler, C. Gillotin, Y. Lou, and D. S. Stein, In vivo effect of alpha-1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 45:852-856 (2001).
17. S. L. Beal and L. B. Sheiner, NONMEM User's Guide. NONMEM Project Group, UCSF, 1992.
18. P. Creticos, W. Adams, B. Petty, L. Lewis, and G. Singh, A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered-dose inhalers. J Allergy Clin Immunol 110:713-720 (2002).
19. H. Leon-Molina, F. Flores-Murrieta, and R. Chapela, Assessment of comparative bioequivalence of two metered-dose inhaler formulations of salbutamol-measuring bronchodilatory effect in patients with asthma. Clin Drug Invest 22(7)):435-441 (2002).
20. K. Parameswaran, Concepts of establishing clinical bioequivalence of chlorofluorocarbon and hydrofluoroalkane b-agonists. J Allergy Clin Immunol 104(6):S243-S245 (1999).
21. G. Singh, W. Adams, L. Lesko, et al., Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling. Clin Pharmacol Ther 66(4)):346-357 (1999).